Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Pilot Diagnostic Study of Perfusion Magnetic Resonance Imaging As a Measurement of Angiogenesis in Patients With Newly Diagnosed Surgically Resectable Brain Tumors (Summary Last Modified 12/2000)

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information
Registry Information

Alternate Title

Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

No phase specified

Diagnostic

Closed

Over 18

NCI

NU-95C1
NCI-G00-1738, NCT00005790

Objectives

I. Correlate the findings of perfusion magnetic resonance imaging with known 
tissue and serum markers of angiogenesis in patients with newly diagnosed 
surgically resectable brain tumors.

Entry Criteria

Disease Characteristics:


Newly diagnosed surgically resectable brain tumor

Prior/Concurrent Therapy:


Biologic therapy:
 Not specified

Chemotherapy:
 No prior chemotherapy

Endocrine therapy:
 Not specified

Radiotherapy:
 No prior radiotherapy

Surgery:
 See Disease Characteristics

Patient Characteristics:


Age:
 Over 18

Performance status:
 Not specified

Life expectancy:
 Not specified

Hematopoietic:
 Not specified

Hepatic:
 Not specified

Renal:
 Not specified

Other:
 Able to tolerate gadopentetate dimeglumine contrast
 Medically stable

Expected Enrollment

A total of 10 patients will be accrued for this study.

Outline

Patients undergo perfusion magnetic resonance imaging (MRI) scanning with 
contrast in conjunction with preoperative conventional MRI scanning with 
contrast.  Patients receive gadopentetate dimeglumine IV over 5 seconds prior 
to perfusion MRI.  Gadopentetate dimeglumine is administered at a slower rate 
prior to conventional MRI.  Patients undergo blood draw to determine urokinase 
type plasminogen activator levels.  After completion of perfusion and 
conventional MRI scanning, brain tumor tissue samples are obtained during 
surgical resection to determine tumor grade and type and urokinase type 
plasminogen activator and basic fibroblast growth factor levels.  If CSF 
removal is required during surgery, then CSF samples are collected to 
determine urokinase type plasminogen activator and basic fibroblast growth 
factor levels.

Trial Contact Information

Trial Lead Organizations

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Hunt Batjer, MD, Protocol chair
Ph: 312-908-5250

Registry Information

Official Title		Perfusion Magnetic Resonance Imaging of Brain Tumors: Correlation with Indicators of Angiogenesis

Trial Start Date		1999-05-10

Registered in ClinicalTrials.gov		NCT00005790

Date Submitted to PDQ		2000-03-03

Information Last Verified		2000-12-01

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.